Improving the health, safety, and quality of life of our youngest patients

Medical devices designed for kids lag five to ten years behind adult technologies. We are funded by the FDA’s Office of Orphan Products Development to help pediatric device innovators accelerate high-value, high-impact solutions towards commercialization and clinical use.

Our Mission

The UCSF-Stanford PDC aims to improve the health, safety, and quality of life of pediatric patients by accelerating high-value, high impact pediatric device solutions at all stages of the total product lifecycle towards commercialization.

2024 Pediatric Device Accelerator Competition

Winners Announced!


Platinum Award - $100,000 

Exhalos / NEC Breath Test - Stanford & Impact1

gold award - $50,000

Dirac - CalTech & UCSF 

SILVER AWARDS - $25,000 each

RAPIDscan - Bloom Standard 

VP.S Encore Peds - Vascular Perfusion Solutions Inc. 

IntelliStent - HeartPoint Global

Neola - Neola Medical Inc. 

bronze awards - mentorship & coaching from pdc

NiADA - Monere Corp.

Pediarity - Gabi SmartCare 

cNIBP Monitor - Esperto Medical Inc. 

TPN 2.0 - TAKEOFF41 Inc.

Resources

Advising

Learn about our tiers of support for pediatric device innovators.

Funding

Congratulations to the PDC Accelerator Shark Tank 2020 awardees!

Education

Resources and video learning modules for pediatric device innovators.

RWE CONSULTING

Harness the power of real-world evidence in your innovation.

Announcements

5th annual Michael R. Harrison Innovation Symposium

March 22, 2024

Events

INNOVATORS FORUM: Tuesdays, 4:00-5:00pm Pacific, Virtual via Zoom

September 12 - Project Medtech: Commercialization strategies for early-stage projects. Speakers: Duane Mancini, MSc and Sean McKibben.


If you are interested in attending or presenting at a future innovators forum, please email usha.thekkedath@ucsf.edu.

News

Featured
Finalist pic 2.jpg
Recap: Michael R. Harrison Innovation Symposium
PDC Pitch Competition 2022 Winners List
New pain management therapy cleared for use in adolescents thanks to a groundbreaking collaboration between the UCSF-Stanford PDC, AtriCure, Inc., and the U.S. FDA

A new pain management therapy has been cleared for use in adolescents thanks to a groundbreaking collaboration between the UCSF-Stanford Pediatric Device Consortium (PDC), AtriCure, Inc., and the U.S. Food and Drug Administration (FDA).

On January 4th, AtriCure announced that the FDA cleared its cryo nerve block (cryoNB) devices cryoICE ® and cryoSPHERE™ for post-operative pain management in patients aged 12 and above. The expanded claims were allowed based on real-world evidence (RWE) developed by researchers at the PDC. RWE is an emerging area of regulatory science where evidence derived from real-world data (captured outside of traditional clinical trial settings) is used to evaluate the potential risks and benefits of a device or drug and inform regulatory decision making.

The UCSF-Stanford Pediatric Device Consortium is funded by the U.S. Food & Drug Administration's Office of Orphan Products Development under grant no. P50FD007967.